Clinical trials: Open Label
Cystic Fibrosis
Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme®
This study evaluates the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients with Cystic Fibrosis previously treated with Pulmozyme®.
- Trial name
- NCT02722122
- Testing
- AIR DNase™
- Where
- 5 sites in Israel
- Volunteers
- 15 people
- Sponsor
- Protalix
Hodgkin Disease
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
The purpose of this study is to assess the safety, tolerability, and anti-tumor activity, as well as confirm the recommended dose of brentuximab vedotin (ADCETRIS) in combination with a multiagent chemotherapy regimen…
- Trial name
- NCT02979522
- Testing
- Brentuximab vedotin, Doxorubicin, Vinblastine
- Where
- 14 sites in United States, Brazil and 2 more
- Volunteers
- 59 people
- Sponsor
- Takeda
Constipation - Functional
Effect and Safety of the Dietary Supplement Mannite in Pediatric Patients With Chronic Functional Constipation
Functional constipation is a widely prevalent pediatric issue, with a prevalence in some studies as high as 32.2%. Treatment consists of a combination of behavioral and pharmacological interventions (mainly, administration of…
- Trial name
- MANNAPED (NCT06404853)
- Testing
- Manna
- Where
- Italy
- Volunteers
- 110 people
- Sponsor
- Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
EPIDERMOLYSIS BULLOSA
Trial To Assess Efficacy Of A Chimeric Skin In Patients With Epidermolysys Bullosa
A phase II, comparative, open label, prospective, multicentre clinical trial where each patient will undergo two procedures; implant of a patch of cultured chimeric skin (experimental therapy) in a half of the skin lesion and an…
- Trial name
- TCEB (NCT00987142)
- Testing
- CX501, Occlusive non adherent dressing
- Where
- 2 sites in Spain
- Volunteers
- 12 people
- Sponsor
- Tigenix S.A.U.
Inherited Metabolic Disorders IMD
Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD)
This study is designed to assess the safety and exploratory efficacy of using HSC835 in patients with Inherited Metabolic Disorders (IMD) undergoing stem cell transplantation.
- Trial name
- NCT02715505
- Testing
- Umbilical cord blood transplantation with HSC835
- Sponsor
- Novartis Pharmaceuticals
Brain and Central Nervous System Tumors
Taurolidine in Treating Patients With Recurrent or Progressive Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of taurolidine in treating patients who have recurrent or…
- Trial name
- NCT00022360
- Testing
- taurolidine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Nephrotic Syndrome in Children
Study of Adrenocorticotropic Hormone on Children With Frequent Relapse or Steroid-dependent Nephrotic Syndrome: a Prospective, Multicenter, Randomized，Open-label Clinical Trial.
Primary nephrotic syndrome accounts for approximately 90% of the total number of nephrotic syndrome in childhood and it is the most common glomerular disease in children.
- Trial name
- NCT06079788
- Testing
- Adrenocorticotrophic Hormone, Steroid
- Where
- 8 sites in China
- Volunteers
- 140 people
- Sponsor
- Mao Jianhua
Human Immunodeficiency Virus
A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)
A study to test the safety and effect of twice daily raltegravir in a diverse cohort of patients currently infected with human immunodeficiency virus (HIV), where at least 50% are African American and at least 25% are female…
- Trial name
- NCT00764946
- Testing
- Comparator: raltegravir
- Volunteers
- 209 people
- Sponsor
- Merck Sharp & Dohme LLC
Apnea, Apnea Neonatal
Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines
A prospective, randomized open-label clinical trial will be conducted from July 2018 to October 2020. Approximately 300 preterm infants will be enrolled across three sites: Duke University Medical Center, the University of North…
- Conditions
- Apnea, Apnea Neonatal, Prematurity
- Trial name
- NCT03530124
- Testing
- PCV13, DTaP, HBV
- Where
- 4 sites in United States
- Volunteers
- 223 people
- Sponsor
- Duke University
HIV Infections
A Study of Zidovudine/Lamivudine and Either Nevirapine or Nelfinavir for Reduction of Mother-to-child HIV Transmission During Breastfeeding
The purpose of the study is to demonstrate that a regimen using highly active antiretroviral therapy (HAART) to maximally suppress maternal viral load in the late antenatal period and during the first six months of lactation is…
- Trial name
- KiBS (NCT00146380)
- Testing
- Zidovudine/Lamivudine and either Nevirapine or Nelfinavir, Breastfeeding for 6 months postpartum
- Where
- Kenya
- Volunteers
- 520 people
- Sponsor
- Centers for Disease Control and Prevention
Human African Trypanosomiasis (HAT), Sleeping Sickness
Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2
This clinical trial is designed to prove the efficacy and safety of Fexinidazole as an oral treatment for human african trypanosomiasis in advanced stage. The Fexinidazole is compared to reference treatment NECT.
- Trial name
- NCT01685827
- Testing
- Fexinidazole, Nifurtimox, Eflornithine
- Where
- 10 sites in Central African Republic, Democratic Republic of the Congo and 1 more
- Volunteers
- 394 people
- Sponsor
- Drugs for Neglected Diseases
Factor XIII Deficiency
A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Congenital deficiency of factor XIII (FXIII) is an extremely rare inherited disorder associated with potentially life-threatening bleeding. Factor XIII Concentrate is given to patients whose blood is lacking factor XIII.
- Trial name
- NCT00885742
- Testing
- FXIII Concentrate (Human)
- Where
- 23 sites in United States, Spain
- Volunteers
- 41 people
- Sponsor
- CSL Behring
HIV-1, HIV Infections
A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents
The purpose of this study is to evaluate the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time), safety, tolerability and antiviral activity to support dose recommendations of TMC114…
- Trial name
- NCT00355524
- Testing
- TMC114, Ritonavir
- Where
- 22 sites in United States, Argentina and 6 more
- Volunteers
- 80 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Alport Syndrome, Focal Segmental Glomerulosclerosis
Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis
This is a Phase 2, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary…
- Trial name
- NCT05267262
- Testing
- R3R01
- Where
- 22 sites in United States, Belgium and 4 more
- Volunteers
- 43 people
- Sponsor
- River 3 Renal Corp.
Hemophilia A
Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures
The purpose of the study is to evaluate the efficacy and safety of BAX 855 in severe hemophilia A previously treated (PTP) males, 12 to 65 years of age who are undergoing elective surgical or other invasive procedures.
- Trial name
- NCT01913405
- Testing
- PEGylated Recombinant factor VIII (rFVIII)
- Where
- 22 sites in United States, Bulgaria and 7 more
- Volunteers
- 30 people
- Sponsor
- Baxalta now part of Shire
Uncomplicated Falciparum Malaria
Azithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Bangladesh
The purpose of this study is to investigate the efficacy of azithromycin combination therapy with artesunate for the treatment of uncomplicated falciparum malaria in Bangladesh.
- Trial name
- NCT00356005
- Testing
- azithromycin plus artesunate, Artesunate
- Where
- Bangladesh
- Volunteers
- 228 people
- Sponsor
- Medical University of Vienna
Inherited Mitochondrial Disease, Including Leigh Syndrome
Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease
To evaluate safety, tolerability and efficacy of cysteamine bitartrate delayed-release capsules (RP103) administered at a target maintenance dose of 1.3 g/m²/day in two divided doses, every 12 hours, for up to 6 months in…
- Trial name
- MITO-001 (NCT02023866)
- Testing
- Cysteamine Bitartrate
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Amgen
Acute Lymphoblastic Leukemia, Chronic Lymphoblastic Leukemia
Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies
This is a single-center, open-label, single-arm study to evaluate the primary safety and efficacy of universal chimeric antigen receptor-modified AT19 cells in patients with relapsed or refractory hematological malignancies.
- Conditions
- Acute Lymphoblastic Leukemia, Chronic Lymphoblastic Leukemia, B-cell Lymphoma
- Trial name
- NCT04796688
- Testing
- Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells
- Where
- 2 sites in China
- Volunteers
- 27 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Diabetes Mellitus, Type 1
Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents
This study will be looking to confirm the effect of dasiglucagon when compared with glucagon for treating very low sugar levels in Asian adults with T1D and the effect of dasiglucagon in Japanese adolescents with T1D.
- Trial name
- NCT06588504
- Testing
- Dasiglucagon, Glucagon
- Where
- Japan
- Volunteers
- 38 people
- Sponsor
- Novo Nordisk A/S
Psoriasis
A Study to Evaluate Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2390g
This is an open-label, multicenter study designed to evaluate the efficacy and safety of efalizumab administered at weekly SC (subcutaneous) doses of 1.0 mg/kg followed by efalizumab taper in subjects with plaque psoriasis who…
- Trial name
- NCT00109252
- Testing
- Raptiva (efalizumab)
- Sponsor
- Genentech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.